Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Wilms Tumor 1Sarcoma, Ewing 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Leukemia 1Hodgkin Disease 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 3Filgrastim 2Drug Therapy 2talazoparib 1sargramostim 1pembrolizumab 1oblimersen 1irinotecan sucrosofate 1etoposide phosphate 1entrectinib 1atezolizumab 1X-Rays 1Vincristine 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Proteasome Inhibitors 1Platinum 1Phantoms, Imaging 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Monatide (IMS 3015) 1Microarray Analysis 1Lenalidomide 1Isotretinoin 1Irinotecan 1Immunomodulating Agents 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Wilms Tumor × Absorptiometry, Photon × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡